
|Videos|June 6, 2017
Dr. Hayes on the Future of Biomarkers for Breast Cancer
Author(s)Daniel F. Hayes, MD
Daniel F. Hayes, MD, professor at the University of Michigan Comprehensive Cancer Center, discusses the future of biomarkers for patients with breast cancer.
Advertisement
Daniel F. Hayes, MD, professor at the University of Michigan Comprehensive Cancer Center, discusses the future of biomarkers for patients with breast cancer.
It is important to determine better ways to identify which patients after 5 years of endocrine-therapy should continue it or switch to another form of therapy, explains Hayes.
According to Hayes, liquid biopsies are exciting and might have a role in determining which patients should be left on their current treatment.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5




































